LSPG(SZ:301111)2022-08-29 16:00Financial Performance - The company's operating revenue for the first half of 2022 was ¥134,095,511.08, a decrease of 19.76% compared to ¥167,126,754.69 in the same period last year[20]. - The net profit attributable to shareholders was ¥25,462,588.00, down 15.64% from ¥30,182,461.57 year-on-year[20]. - The net profit after deducting non-recurring gains and losses was ¥15,374,644.30, reflecting a significant decline of 42.31% compared to ¥26,651,016.66 in the previous year[20]. - The net cash flow from operating activities was ¥22,983,043.12, a decrease of 53.52% from ¥49,446,454.87 in the same period last year[20]. - Basic earnings per share were ¥0.1591, down 36.74% from ¥0.2515 in the previous year[20]. - Total operating revenue for the first half of 2022 was ¥134,095,511.08, a decrease of 19.8% compared to ¥167,126,754.69 in the first half of 2021[147]. - Total operating costs decreased to ¥116,962,376.67 in the first half of 2022, down 14.2% from ¥136,364,286.55 in the same period of 2021[148]. - Net profit for the first half of 2022 was ¥25,462,588.00, representing a decline of 15.7% from ¥30,182,461.57 in the first half of 2021[149]. - The total profit for the first half of 2022 was ¥28,757,180.19, down from ¥35,055,549.07 in the first half of 2021[148]. Assets and Liabilities - Total assets at the end of the reporting period were ¥815,877,279.89, a decrease of 1.25% from ¥826,198,080.76 at the end of the previous year[20]. - The net assets attributable to shareholders were ¥750,716,220.01, showing a slight decrease of 0.02% from ¥750,853,632.01 at the end of the previous year[20]. - Current assets totaled CNY 682,231,264.41, down from CNY 708,843,441.99, indicating a decrease of about 3.73%[139]. - Total liabilities decreased from CNY 75,344,448.75 to CNY 65,161,059.88, a decline of about 13.9%[141]. - Non-current assets totaled CNY 133,646,015.48, up from CNY 117,354,638.77, reflecting an increase of approximately 13.9%[140]. Investment and R&D - The company reported a total non-recurring gains and losses of RMB 10,087,943.70, with government subsidies contributing RMB 4,381,442.77 and investment management gains of RMB 6,013,612.39[24]. - The company’s R&D investment was ¥5,133,172.71, reflecting a decrease of 4.07% year-on-year[42]. - The company launched 2 new R&D projects during the reporting period, focusing on innovative drug formulations and improvements[37]. - The company has established a mature R&D system and team, focusing on the innovation and improvement of traditional Chinese medicine products[74]. Market and Sales - The new retail division generated sales revenue of 12.15 million yuan, a significant increase of 343.01% year-on-year, accounting for 9.06% of total revenue, up from 1.64% in the previous year[37]. - Sales expenses increased by 2.43% year-on-year as the company intensified marketing efforts to expand its sales market[36]. - The company has a strategic focus on expanding its product offerings and enhancing its market presence in the pharmaceutical sector[29]. - The company has developed high internal control standards for product quality, exceeding legal requirements, with several products recognized for their quality[40]. Cash Flow - The net cash flow from operating activities for the first half of 2022 was ¥22,983,043.12, a decrease of 53.6% compared to ¥49,446,454.87 in the same period of 2021[154]. - The total cash outflow from financing activities was ¥34,802,450.01, compared to only ¥600,000.00 in the same period last year, indicating increased dividend payments and interest[157]. - The net cash outflow from investment activities reached ¥331,641,140.23, compared to a net outflow of ¥29,909,171.31 in the previous year, reflecting increased investment expenditures[157]. Corporate Governance - The company plans not to distribute cash dividends or issue bonus shares for the semi-annual period[83]. - There were no changes in the company's board of directors, supervisors, or senior management during the reporting period[82]. - The company has not implemented any stock incentive plans, employee stock ownership plans, or other employee incentive measures during the reporting period[84]. - The financial report for the first half of 2022 has not been audited[137]. Compliance and Risk Management - The management has highlighted the importance of risk awareness regarding future plans and projections[3]. - The company faces risks related to policy changes in the pharmaceutical industry, which could impact its operations if not addressed effectively[75]. - The company has implemented strict quality control measures to ensure its products meet safety and efficacy standards[75]. - The company maintains a strong commitment to environmental protection, adhering to relevant laws and regulations, and is not classified as a key pollutant discharge unit[87]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 18,859[125]. - Guangdong Jino Health Technology Co., Ltd. holds 45.00% of shares, totaling 72,000,000 shares[125]. - The company’s shareholding structure shows a decrease in state-owned shares by 5,861 shares, maintaining a total of 5,084,760 shares (3.18%)[120]. - The company has issued a total of 2,463,200 restricted shares during the reporting period[126]. Strategic Initiatives - The company is actively involved in the research and development of traditional Chinese medicine, aligning with national policies to promote the industry[29]. - The company is positioned to benefit from favorable government policies aimed at enhancing the development of traditional Chinese medicine[29]. - The company has established a stable supply chain and maintains fair supplier management procedures to protect supplier rights[90].